Home glucose monitoring fails to improve control of type 2 diabetes

Patients with type 2 diabetes not treated with insulin were unable to improve glycemic control after a year by self-monitoring blood glucose levels, according to a study published in JAMA Internal Medicine.

Self-monitoring may allow patients feel more engaged in their care, but results show such actions do not translate to improved control of diabetes. This study evaluated three separate approaches to self-monitoring of blood glucose (SMBG) to evaluate effectiveness. Led by Katrina E. Donahue, MD, MPH, of the University of North Carolina at Chapel Hill, the study included enrolled 418 participants from 15 primary care physicians with non-insulin-treated type 2 diabetes.

Participants were assigned into three groups. One did not participate in SMBG, another performed SMBG once daily and a third performed SMBG once a day and received feedback messages through the glucose monitors. Results measured hemoglobin A1c levels in all groups as well as quality of life after one year.

Overall, patients in all groups showed no improvements in glycemic control or quality of life.

“In patients with non–insulin-treated type 2 diabetes, we observed no clinically or statistically significant differences at 1 year in glycemic control or health-related quality of life between patients who performed SMBG compared with those who did not perform SMBG,” concluded Donahue and colleagues. “The addition of this type of tailored feedback provided through messaging via a meter did not provide any advantage in glycemic control.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.